Shots:
- The US FDA has granted BDD to Avvio ELS for minimally invasive, anesthesia-independent kidney stone treatment
- AVVIO ELS will be investigated in a pivotal ELS trial across the US following IDE approval, with US commercial launch planned in 2026, pending FDA clearance
- The AVVIO ELS uses microbubble-enhanced acoustic cavitation lithotripsy to enable minimally invasive kidney stone treatment in ambulatory surgery centers & cystoscopy suites, eliminating the need for general anesthesia, fluoroscopy, or costly equipment
Ref: Businesswire | Image: Avvio Medical| Press Release
Related News:- Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
